NIH Establishes Pandemic Preparedness Research Network

The National Institutes of Health (NIH) recently launched the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness network (ReVAMPP), which aims to combat high-priority pathogens that pose significant threats to human health.

Through this initiative, NIH will focus on developing vaccines and monoclonal antibodies for pathogens that currently have no available therapeutics. The network will prioritize viruses from families such as Flaviviridae, Paramyxoviridae and Togaviridae, many of which are high-priority pathogens with the potential to cause serious human disease.

ReVAMPP will study "prototype pathogens" to create a knowledge base applicable to similar viruses, building on previous successes like the work on Middle East respiratory syndrome coronavirus, which informed the agency’s COVID-19 response.

NIH's National Institute of Allergy and Infectious Diseases (NIAID) expects to invest $100 million annually in the program, supporting pandemic preparedness and facilitating collaboration among research centers across the United States.